"[Generic drugs] with a
small market, they're typically [the] ones with a small number of competitors.
The sort of canary in the coal mine is when the prices go up dramatically over
a couple of years, because there's really no economic justification for a generic
drug increasing their prices dramatically."
— Gerard Anderson, a professor at the Johns Hopkins University
Bloomberg School of Public Health, talked with AIS's Health Plan Weekly about
the potential impact of California's proposed generic contracting program,
which would see the state establish its own generic drug label in an effort to
lower prices.
No comments:
Post a Comment